← Back to Clinical Trials
Recruiting NCT07536503

NCT07536503 Effects of Sleep Quality on Functional and Cognitive Outcomes in Multiple Sclerosis

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07536503
Status Recruiting
Phase
Sponsor Büşra Seçkinoğulları Korkusuz
Condition Multiple Sclerosis
Study Type OBSERVATIONAL
Enrollment 80 participants
Start Date 2026-05-01
Primary Completion 2026-07-01

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 65 Years
Study Type OBSERVATIONAL

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 80 participants in total. It began in 2026-05-01 with a primary completion date of 2026-07-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The goal of this observational study is to investigate the effects of sleep quality on cognitive flexibility, physical activity level, body awareness, and reaction time in individuals with Multiple Sclerosis. The main question it aims to answer is: Does sleep quality influence cognitive flexibility, physical activity level, body awareness, and reaction time in individuals with Multiple Sclerosis? Researchers will compare individuals with good and poor sleep quality to determine whether differences in sleep quality result in variations in cognitive and physical performance outcomes. Participants will complete standardized assessments of sleep quality, cognitive flexibility, physical activity, and body awareness, and will perform a computer-based reaction time test. In addition, participants will wear a wearable activity tracker for 7 days to objectively measure physical activity levels.

Eligibility Criteria

Inclusion Criteria: * Age between 18 and 65 years * Diagnosis of Multiple Sclerosis * Montreal Cognitive Assessment (MoCA) score ≥24 * Expanded Disability Status Scale (EDSS) score between 0 and 6.5 * No relapse within the last 3 months * Voluntary participation with written informed consent Exclusion Criteria: * Presence of other neurological, psychiatric, or systemic diseases * Severe visual, auditory, or balance impairments * History of surgery within the last 6 months * Use of sleep medication or central nervous system-affecting drugs * Severe orthopedic deformity or pain

Contact & Investigator

Central Contact

Süleyman Korkusuz, PhD

✉ suleyman.korkusuz@atilim.edu.tr

📞 +905388675480

Principal Investigator

Büşra S Korkusuz

STUDY CHAIR

Ankara University

Frequently Asked Questions

Who can join the NCT07536503 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 65 Years, studying Multiple Sclerosis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07536503 currently recruiting?

Yes, NCT07536503 is actively recruiting participants. Contact the research team at suleyman.korkusuz@atilim.edu.tr for enrollment information.

Where is the NCT07536503 trial being conducted?

This trial is being conducted at Ankara, Turkey (Türkiye).

Who is sponsoring the NCT07536503 clinical trial?

NCT07536503 is sponsored by Büşra Seçkinoğulları Korkusuz. The principal investigator is Büşra S Korkusuz at Ankara University. The trial plans to enroll 80 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology